Montaldi, Ana P.; Lima, Sarah Caroline Gomes de 
; Godoy, Paulo Roberto D'Auria Vieira; Xavier, Danilo Jordão; Sakamoto-Hojo, Elza Tiemi
Source: Oncology Reports. Unidades: FFCLRP, FMRP
Subjects: ANTINEOPLÁSICOS, FARMACOLOGIA, APOPTOSE, NEOPLASIAS CEREBRAIS, PATOLOGIA, GLIOMA, METABOLISMO, PROTEÍNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MONTALDI, Ana P. et al. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. Oncology Reports, v. 44, n. 5, p. 2275-2287, 2020Tradução . . Disponível em: https://doi.org/10.3892/or.2020.7756. Acesso em: 17 nov. 2024.APA
Montaldi, A. P., Lima, S. C. G. de, Godoy, P. R. D. 'A. V., Xavier, D. J., & Sakamoto-Hojo, E. T. (2020). PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. Oncology Reports, 44( 5), 2275-2287. doi:10.3892/or.2020.7756NLM
Montaldi AP, Lima SCG de, Godoy PRD'AV, Xavier DJ, Sakamoto-Hojo ET. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency [Internet]. Oncology Reports. 2020 ; 44( 5): 2275-2287.[citado 2024 nov. 17 ] Available from: https://doi.org/10.3892/or.2020.7756Vancouver
Montaldi AP, Lima SCG de, Godoy PRD'AV, Xavier DJ, Sakamoto-Hojo ET. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency [Internet]. Oncology Reports. 2020 ; 44( 5): 2275-2287.[citado 2024 nov. 17 ] Available from: https://doi.org/10.3892/or.2020.7756
